Despite market volatility, platform biotechnology, especially in modalities like mRNA, gene editing, and targeted protein degradation has seen renewed investor confidence. Teams with clearly articulated platform value, scalable infrastructure, and translational evidence are best positioned to attract funding and strategic partnerships.